F-1: Trinity Biotech Secures $25M Equity Line, Faces Nasdaq Delisting Threat

Trinity Biotech PLC has entered a $25 million equity purchase agreement while simultaneously addressing Nasdaq non-compliance issues and significant debt obligations.

Summary

• Trinity Biotech PLC filed an F-1 registration statement for the resale of up to 35,282,966 American Depositary Shares (ADSs) by YA II PN, LTD.
• The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. on February 24, 2026, allowing it to sell up to $25 million in ADSs at its option.
• The pricing for these sales will be 97% of the lowest daily volume-weighted average price (VWAP) over a three-trading-day period or 95% of the VWAP over a one-trading-day period.
• Trinity Biotech paid a $35,000 structuring fee and issued 175,537 Commitment ADSs to YA II PN, LTD. for entering the SEPA.
• The company will not receive proceeds from the resale of ADSs by YA II PN, LTD., but may receive up to $25 million from its direct sales to the investor under the SEPA.
• Proceeds from company sales under the SEPA are intended for operating expenses, working capital, strategic, and general corporate purposes.
• As of December 31, 2025, total indebtedness was approximately US$134.58 million, with a term loan of US$100.82 million due January 2027.
• On December 22, 2025, the company secured an additional $5 million term loan and issued a $96,161,421.33 convertible promissory note to Perceptive Credit Holdings III, L.P.
• Up to $60 million of this convertible note is convertible into ADSs at 97% of VWAP, with a floor price of $1.03, subject to a 9.9% beneficial ownership cap.
• A $5 million milestone payment obligation and a $7.5 million contingent payment obligation related to the Waveform Technologies Inc. acquisition are also convertible into ADSs by Perceptive Credit Holdings II, L.P.
• The company received Nasdaq deficiency notices on February 11, 2026, for not meeting the minimum $1.00 bid price and on February 19, 2026, for not meeting the $15 million minimum market value of publicly held shares (MVPHS).
• Shareholders approved reducing the nominal value of ordinary shares from $0.0109 to $0.0001 and increasing authorized share capital to 16,654,000,000 ordinary shares on September 30, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the severe Nasdaq non-compliance issues, substantial debt burden, and the highly dilutive nature of the recent financing arrangements, which collectively signal significant financial distress and operational challenges.

Positives

• Secured a Standby Equity Purchase Agreement (SEPA) for up to $25 million, providing a potential source of capital for operating expenses, working capital, and strategic purposes.
• Obtained an additional $5 million term loan borrowing on December 22, 2025, providing immediate liquidity.
• Converted significant debt obligations (up to $60 million of a convertible note and $12.5 million in other payment obligations) into convertible instruments, potentially reducing immediate cash outflow for debt service.
• Increased authorized share capital to 16,654,000,000 ordinary shares, providing flexibility for future equity issuances.

Negatives

• The company is currently non-compliant with Nasdaq's minimum bid price ($1.00) and minimum market value of publicly held shares ($15 million) requirements, risking delisting.
• Significant outstanding debt of approximately US$134.58 million as of December 31, 2025, with a substantial portion (US$100.82 million) of the term loan due in January 2027.
• The equity financing under the SEPA involves selling ADSs at a discount (95% or 97% of VWAP), which could lead to dilution for existing shareholders.
• The conversion of Perceptive debt obligations into ADSs also carries a risk of substantial dilution to existing shareholders.
• The company will not receive any proceeds from the resale of ADSs by the Selling Securityholder, limiting immediate cash inflow from this registration.
• The actual amount of proceeds from the SEPA is uncertain and depends on market conditions and the company's discretion to sell.

Risks

• Substantial indebtedness of approximately US$134.58 million as of December 31, 2025, which could impair flexibility and access to capital.
• Uncertainty regarding the ability to generate or raise sufficient funds to repay debt as it becomes due and to continue as a going concern.
• Risk of delisting from The Nasdaq Global Select Market due to non-compliance with minimum bid price ($1.00) and minimum market value of publicly held shares ($15 million) requirements.
• Potential adverse effects of delisting, including reduced liquidity, decreased market price, "penny stock" designation, and impaired ability to raise future capital.
• Significant dilution to existing shareholders from the issuance and sale of ADSs under the Standby Equity Purchase Agreement (SEPA) and the conversion of Perceptive Conversion Obligations (up to 1,407,767,000 ordinary shares).
• The sale of a substantial number of ADSs by the Selling Securityholder could depress the market price of the company's ADSs.
• Exposure to global economic conditions, including ongoing effects of the COVID-19 pandemic, hostilities (Russia-Ukraine, Hamas-Israel), and political instability.
• Challenges in successfully developing and commercializing new products, including biosensor-related products and the continuous glucose monitoring (CGM) product.
• Inability to obtain additional funding on acceptable terms or in sufficient amounts could lead to delays, scaling back, or discontinuation of operations, asset sales, or cessation of trading.

Future Outlook

The company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring (CGM) product. Future plans include successfully commercializing new products, potentially entering strategic relationships, and acquiring or in-licensing new product candidates. The company acknowledges that its ability to continue as a going concern depends on generating or raising sufficient funds to repay its substantial debt and fund operations.

Management Comments

• "We intend to use any proceeds from the Selling Securityholder that we receive under the Purchase Agreement for operating expenses, working capital, strategic and general corporate purposes."
• "Our management will have broad discretion to determine the specific use for the net proceeds and we may use the proceeds for purposes that are not contemplated at the time of this offering."

Industry Context

StockSavvy.ai notes that Trinity Biotech's focus on diabetes management solutions and human diagnostics, particularly wearable biosensors and continuous glucose monitoring (CGM), places it in a high-growth, competitive segment of the biotechnology and medical device industry. The strategic equity financing and debt restructuring efforts are critical for companies in this space to fund R&D and commercialization, especially given the capital-intensive nature of product development and market entry. However, the ongoing Nasdaq compliance issues highlight the challenges smaller-cap biotech firms face in maintaining market visibility and access to capital amidst operational and financial pressures.

Comparison to Industry Standards

• The company's current ADS price of $0.75 and non-compliance with Nasdaq's $1.00 minimum bid price and $15 million MVPHS requirements indicate a significant underperformance compared to established industry leaders in diagnostics and diabetes management, such as Abbott Laboratories (ABT) or Dexcom (DXCM), which maintain robust market capitalizations and share prices well above listing thresholds.
• The reliance on a Standby Equity Purchase Agreement (SEPA) and convertible debt with significant discounts to VWAP (95-97%) suggests a more distressed financing approach, contrasting with larger, more stable industry players that typically access capital markets through traditional equity offerings or investment-grade debt at more favorable terms.
• The substantial debt load of approximately $134.58 million relative to its market capitalization (implied by the low ADS price and MVPHS non-compliance) is considerably higher than the leverage ratios of many profitable, well-capitalized peers in the diagnostics sector, indicating elevated financial risk.
• The acquisition of CGM assets from Waveform Technologies Inc. and the stated intent to develop a CGM product positions Trinity Biotech in a market with strong competitors like Dexcom and Abbott, which have already established significant market share and advanced product pipelines. Trinity Biotech's ability to compete effectively with its current financial constraints and market valuation is a key concern.

Corporate Governance

Related Party Transactions

• Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (the Investor/Selling Securityholder) for up to $25 million in ADSs.
• Credit Agreement and Convertible Promissory Note with Perceptive Credit Holdings III, L.P. (PCH III) for an additional $5 million term loan and a $96.16 million convertible note.
• Conversion Rights Agreement with Perceptive Credit Holdings II, L.P. (PCH II) for conversion of $5 million milestone payment and $7.5 million contingent payment into ADSs.
• Registration Rights Agreement with Perceptive Credit Holdings III, L.P. and Perceptive Credit Holdings II, L.P. for the registration of ADSs and ordinary shares issuable upon conversion of Perceptive Conversion Documents.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the Standby Equity Purchase Agreement (SEPA) and the conversion of substantial debt into equity. Also, risk of delisting from Nasdaq could severely impact liquidity and share price.
• Creditors (Perceptive Credit Holdings): Have converted a significant portion of their debt into convertible instruments, providing them with potential upside through equity conversion while reducing the company's immediate cash debt service obligations.
• Employees: The company's ability to continue as a going concern and fund operations directly impacts job security and future prospects.
• Customers: Potential delays or scaling back of product development and commercialization could affect product availability and innovation, particularly for new biosensor and CGM products.
• Suppliers: Financial instability and potential operational cutbacks could impact relationships and payment terms with suppliers.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by August 10, 2026, by having the closing bid price meet or exceed $1.00 for at least ten consecutive business days.
• Regain compliance with Nasdaq's minimum market value of publicly held shares (MVPHS) requirement by August 18, 2026, by having the MVPHS exceed $15 million for a minimum of ten consecutive business days.
• Potentially appeal any delisting determination from Nasdaq if compliance is not regained.
• Utilize the Standby Equity Purchase Agreement (SEPA) to sell ADSs to YA II PN, LTD. for up to $25 million, at the company's discretion, until February 24, 2029.
• Continue efforts to develop and commercialize new products, including biosensor devices and a continuous glucose monitoring (CGM) product.
• Address the substantial indebtedness, including the term loan repayable in January 2027, potentially through refinancing or further equity offerings.
• Directors and officers of the company will be required to file Section 16(a) reports with the SEC starting March 18, 2026.

Key Dates

Recommendation

The filing reveals a company in significant financial distress, evidenced by substantial debt, a precarious Nasdaq listing status with multiple non-compliance notices, and a reliance on highly dilutive financing mechanisms like the Standby Equity Purchase Agreement and convertible debt. The current ADS price is well below Nasdaq's minimum bid requirement, and the risk of delisting is high, which would severely impair liquidity and investor confidence. While the company is attempting to secure capital, the terms are unfavorable and indicate a desperate need for funds. The potential for massive dilution from both the SEPA and the Perceptive debt conversions, coupled with the looming debt repayment in January 2027, presents an extremely high-risk profile. A seasoned investor would likely view this as a strong sell due to the severe downside risks and lack of clear path to sustainable profitability or market recovery.

Keywords

Trinity Biotech, TRIB, SEC F-1, Secondary Offering, ADS, American Depositary Shares, Equity Purchase Agreement, YA II PN LTD, Nasdaq Delisting, Debt Financing, Convertible Note, Perceptive Credit Holdings, Biosensors, Continuous Glucose Monitoring, CGM, Dilution, Financial Risk, Biotechnology, Diagnostics